ABSTRACT BOOK ABSTRACTS



A new ERA for global Dermatology 10 - 15 JUNE 2019 MILAN, ITALY

MEDICAL THERAPIES AND PHARMACOLOGY

## ANTI-TNF-ALPHA BIOSIMILARS IN THE TREATMENT OF PLAQUE-TYPE PSORIASIS AND PSORIATIC ARTHRITIS: A REAL LIFE, SINGLE CENTER STUDY ON EFFECTIVENESS, SAFETY AND PHARMACOECONOMIC IMPACT.

Alessandro Giunta<sup>(1)</sup> - Valeria Manfreda<sup>(1)</sup> - Maria Esposito<sup>(1)</sup> - Eleonora Di Matteo<sup>(1)</sup> - Antonio Massaro<sup>(2)</sup> - Caterina Lanna<sup>(1)</sup> - Arianna Piccolo<sup>(1)</sup> - Luca Bianchi<sup>(1)</sup>

University Of Rome Tor Vergata, Dermatology, Rome, Italy<sup>(1)</sup> - University Of Rome Tor Vergata, Dermatology, Roma, Italy<sup>(2)</sup>

Introduction: Extrapolation of clinical data from other indications after a similarity to a reference medicinal product is established is an important concept in the development of biosimilars. Though, few data on the etanercept biosimilar SB4 in psoriasis are available and still no data are available for adalimumab biosimilar.

Objective: Our 3-years ongoing Investigator Initiated founded trial (reference number for founding source: ITA-BIO-18-11403) has as primary objective to evaluate real-life effectiveness and safety of anti-TNF-alpha biosimilars in the treatment of plaque-type psoriasis and psoriatic arthritis.

Methods: We will evaluate the proportion of patients achieving a 75% reduction of PASI at week 24 from baseline in both naïve and transioned patients. In addition, in patients affected by psoriatic arthritis, the proportion of patients achieving a 20% reduction of ACR will be evaluated at the same time points in both naïve and transitioned patients.

Results: To date, we enrolled 91 patients of the 350 prevised patients: 43 were males and mean age was 56.69 years (range: 17.08-83.89). 22 patients (24.18%) and 69 patients (78.82%) were affected by plaque-type psoriasis and psoriatic arthritis, respectively. All patients' comorbidities and previous therapies were recorded. 52/91 patients have an observation period of at least 1 year (mead 555.40 days, range 363-874). Our presentation will show preliminary results of the ongoing study. To date, efficacy data on 52 patients showed a remarkably improvement of mean PASI from BL (PASI=6.57) to week 24 (PASI=1.2) and 48 (PASI=0.8). No serious adverse events has been reported or observed.

Conclusions: Although prelimary, our data demonstrates that etanercept biosimilar SB4 is significantly effective in inducing remission of plaque-type psoriasis and psoriatic arthritis.





